CRSP N - CRISPR Therapeutics AG (BMV) Stock - Inntjeningshistorikk

CRISPR Therapeutics AG
MX ˙ BMV
Kommende inntjeningsdatoer for CRISPR Therapeutics AG
Det er ingen kjent inntjeningsmelding for CRISPR Therapeutics AG planlagt for øyeblikket.
Dato Inntektsestimat EPS-estimat Tid
Ingen kunngjøringer planlagt for øyeblikket.
Inntjeningshistorikk

Dette kortet viser GAAP-inntjeningshistorikken for CRISPR Therapeutics AG.

Sluttdato for perioden GAAP Resultat per aksje grunnleggende (kvartalsvis) GAAP Resultat per aksje utvannet (kvartalsvis) GAAP Resultat per aksje grunnleggende (TTM) GAAP Resultat per aksje utvannet (TTM) Valuta
2025-06-30 −2,40 −2,40 −5,44 −5,43 USD
2025-03-31 −1,58 −1,58 −4,52 −4,51 USD
2024-12-31 −0,44 −0,43 −4,34 −4,34 USD
2024-09-30 −1,01 −1,01 −2,89 −2,90 USD
2024-06-30 −1,49 −1,49 −3,26 −3,27 USD
2024-03-31 −1,43 −1,43 −2,71 −2,72 USD
2023-12-31 1,12 1,09 −1,94 −1,94 USD
2023-09-30 −1,41 −1,41 −4,48 −4,47 USD
2023-06-30 −0,98 −0,98 −5,30 −5,30 USD
2023-03-31 −0,67 −0,67 −6,71 −6,70 USD
2022-12-31 −1,41 −1,41 −8,36 −8,36 USD
2022-09-30 −2,24 −2,24 −8,80 −8,80 USD
2022-06-30 −2,40 −2,40 −8,24 −8,23 USD
2022-03-31 −2,32 −2,32 4,07 3,86 USD
2021-12-31 −1,84 −1,84 4,97 4,70 USD
2021-09-30 −1,67 −1,67 5,52 5,26 USD
2021-06-30 10,01 9,44 6,11 5,90 USD
2021-03-31 −1,51 −1,51 −5,65 −5,64 USD
2020-12-31 −1,50 −1,50 −5,29 −5,29 USD
2020-09-30 −1,32 −1,32 −3,38 −3,39 USD
Resultatoverraskelser
Ingen data tilgjengelig.
Før og etter resultatdrift
Dette kortet viser historisk før- og etter-resultatdrift for selskapet.
Ingen data tilgjengelig.
Other Listings
GB:0VRQ
US:CRSP USD 55,89
CH:1CG
DE:1CG
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista